Research progress on new drugs for primary immune thrombocytopenia
Primary immune thrombocytopenia(ITP)is an autoimmune disease characterized by increased platelet destruction and inadequate megakaryocyte maturation.In recent years,with the in-depth study of the pathogenesis of ITP,new drugs related to spleen tyrosine kinase,Bruton's tyrosine kinase,neonatal Fc receptor inhibitors,platelet desialylation,B-cell activating factor and classical complement pathway have gradually become the focus of ITP treatment.This article reviewed the research progress on new ITP drugs in recent years,aiming to provide reference for selecting appropriate individualized treatment according to the pathogenesis and economic situation in the future.
NETL
NSTL
万方数据
